| S8893 |
Firsocostat (GS-0976, ND-630)
|
Firsocostat (GS-0976, ND-630)是acetyl CoA carboxylase (ACC)的一種可逆抑制劑，對hACC1和hACC2的IC50分別為2.1 nM，6.1 nM。 |
-
Adv Sci (Weinh), 2024, 11(46):e2401311
-
Nat Commun, 2023, 14(1):1362
-
Genome Med, 2022, 14(1):67
|
|
| S6753 |
CP 640186
|
CP 640186是ACC (Acetyl-CoA carboxylase)抑制劑，對大鼠肝臟ACC1和骨骼肌ACC2的IC50分別為53 nM和61 nM。 |
-
Exp Ther Med, 2020, 20(1):521-529
-
Molecules, 2015, 20(9):16221-34
-
Molecules, 2015, 20(9):16221-34
|
|
| S8377 |
ND646
|
ND-646 是一種 ACC (Acetyl-coA carboxylase) enzymes 的變構(gòu)抑制劑，可防止ACC亞基二聚化，從而抑制脂肪酸合成，對hACC1和hACC2的IC50值分別為3.5 nM和4.1 nM。 |
-
Cancer Discov, 2023, 13(2):496-515
-
Cancer Sci, 2023, 114(4):1651-1662
-
Cancer Sci, 2023, 114(4):1651-1662
|
|
| S6690 |
TOFA
|
TOFA 是acetyl-CoA carboxylase-α (ACCA)的變構(gòu)抑制劑。在細胞內(nèi)TOFA轉(zhuǎn)化為TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA)，對ACCA具有變構(gòu)抑制作用。 TOFA阻止脂肪酸合成，并以劑量依賴性方式誘導(dǎo)細胞死亡。 |
-
J Clin Invest, 2025, e190215
-
J Transl Med, 2025, 23(1):1055
-
Oncotarget, 2025, 16:532-544
|
|
| S6672 |
PF-05175157
|
PF-05175157是一種廣譜有效的ACC抑制劑，對人ACC1，人ACC2，大鼠ACC1和大鼠ACC2的IC50分別為27.0 nM、33.0 nM、23.5 nM和50.4 nM。 |
-
Nat Commun, 2025, 16(1):509
-
Cancer Cell Int, 2023, 23(1):83
-
Liver Res-Prc, 2023, Volume 7, Issue 2 Pages 124-135
|
|
| F0270 |
Acetyl-CoA Carboxylase Antibody [N24C17]
|
Acetyl-CoA Carboxylase Rabbit mAb recognizes endogenous levels of total Acetyl-CoA Carboxylase protein. |
|
|
| S5519 |
4-Methylsalicylic acid
|
4-Methylsalicylic acid (m-Cresotic acid, 2-Hydroxy-4-methylbenzoic acid, m-Cresotinic acid, 2-Hydroxy-p-toluic acid) is used to inhibit the medium chain acyl-CoA synthetase. |
|
|
| S6145 |
PF-05221304
|
PF-05221304 是一種口服可生物利用的，肝靶向的 acetyl-CoA carboxylase (ACC) 的抑制劑，是一種催化脂肪從頭生成(DNL)的第一步的酶。 |
|
|
| S6112 |
Oxalacetic acid
|
Oxalacetic acid (Oxaloacetic acid, 2-Oxosuccinic acid, Ketosuccinic acid)是三羧酸循環(huán)的中間物，它與乙酰輔酶A經(jīng)檸檬酸合酶催化反應(yīng)生成檸檬酸鹽。它還參與糖原異生、尿素循環(huán)、乙醛酸循環(huán)、氨基酸合成和脂肪酸合成等過程。Oxaloacetate是Complex II的抑制劑。 |
|
|
| S8893 |
Firsocostat (GS-0976, ND-630)
|
Firsocostat (GS-0976, ND-630)是acetyl CoA carboxylase (ACC)的一種可逆抑制劑，對hACC1和hACC2的IC50分別為2.1 nM，6.1 nM。 |
- Adv Sci (Weinh), 2024, 11(46):e2401311
- Nat Commun, 2023, 14(1):1362
- Genome Med, 2022, 14(1):67
|
|
| S6753 |
CP 640186
|
CP 640186是ACC (Acetyl-CoA carboxylase)抑制劑，對大鼠肝臟ACC1和骨骼肌ACC2的IC50分別為53 nM和61 nM。 |
- Exp Ther Med, 2020, 20(1):521-529
- Molecules, 2015, 20(9):16221-34
- Molecules, 2015, 20(9):16221-34
|
|
| S8377 |
ND646
|
ND-646 是一種 ACC (Acetyl-coA carboxylase) enzymes 的變構(gòu)抑制劑，可防止ACC亞基二聚化，從而抑制脂肪酸合成，對hACC1和hACC2的IC50值分別為3.5 nM和4.1 nM。 |
- Cancer Discov, 2023, 13(2):496-515
- Cancer Sci, 2023, 114(4):1651-1662
- Cancer Sci, 2023, 114(4):1651-1662
|
|
| S6690 |
TOFA
|
TOFA 是acetyl-CoA carboxylase-α (ACCA)的變構(gòu)抑制劑。在細胞內(nèi)TOFA轉(zhuǎn)化為TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA)，對ACCA具有變構(gòu)抑制作用。 TOFA阻止脂肪酸合成，并以劑量依賴性方式誘導(dǎo)細胞死亡。 |
- J Clin Invest, 2025, e190215
- J Transl Med, 2025, 23(1):1055
- Oncotarget, 2025, 16:532-544
|
|
| S6672 |
PF-05175157
|
PF-05175157是一種廣譜有效的ACC抑制劑，對人ACC1，人ACC2，大鼠ACC1和大鼠ACC2的IC50分別為27.0 nM、33.0 nM、23.5 nM和50.4 nM。 |
- Nat Commun, 2025, 16(1):509
- Cancer Cell Int, 2023, 23(1):83
- Liver Res-Prc, 2023, Volume 7, Issue 2 Pages 124-135
|
|
| S5519 |
4-Methylsalicylic acid
|
4-Methylsalicylic acid (m-Cresotic acid, 2-Hydroxy-4-methylbenzoic acid, m-Cresotinic acid, 2-Hydroxy-p-toluic acid) is used to inhibit the medium chain acyl-CoA synthetase. |
|
|
| S6145 |
PF-05221304
|
PF-05221304 是一種口服可生物利用的，肝靶向的 acetyl-CoA carboxylase (ACC) 的抑制劑，是一種催化脂肪從頭生成(DNL)的第一步的酶。 |
|
|
